SOLIRIS (eculizumab): The first treatment specifically approved for PNH

My PNH Story.

Real stories from real people about the disease — and SOLIRIS treatment

If you or a loved one is affected by PNH, you're not alone. While these stories — like PNH — are unique to each individual, confronting PNH with strength and courage is something everyone touched by the disease shares.

As you read the following stories, remember that the signs and symptoms of PNH are highly variable and differ from patient to patient. Chronic hemolysis, the underlying cause of PNH in all patients, is the cause of these signs and symptoms.1 Your own experiences may differ from those described in these stories.

If you're interested in sharing your story, email us here.

For important safety information for patients on SOLIRIS® therapy, click here.

Margarita — Learn how Margarita went from living in her laundry room to living for Friday night
Greg — COMING SOON
Drew — COMING SOON

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.